ERBB2 and breast cancer: On the other hand, it’s worth exploring whether ADCs originally designed for other tumors with HER-2 targets will also work in urothelial carcinoma, such as Trastuzumab emtansine (Kadcyla), which the FDA approved for use in breast cancer in 2013 (57).